Fundamental Analysis of MARINUS PHARMACEUTICALS INC(NASDAQ:MRNS) stock

Fundamental Rating

MRNS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of MRNS have multiple concerns. MRNS is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MRNS has reported negative net income.

MRNS had a negative operating cash flow in the past year.

In the past 5 years MRNS always reported negative net income.

In the past 5 years MRNS always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -171.37%, MRNS is not doing good in the industry: 89.06% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-171.37%
ROE	N/A
ROIC	N/A

ROA(3y)-54.19%

ROA(5y)-53.62%

ROE(3y)-348.39%

ROE(5y)-232.49%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MRNS has a Gross Margin of 90.62%. This is amongst the best in the industry. MRNS outperforms 95.31% of its industry peers.

The Profit Margin and Operating Margin are not available for MRNS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	90.62%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MRNS does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for MRNS has been increased compared to 1 year ago.

MRNS has more shares outstanding than it did 5 years ago.

The debt/assets ratio for MRNS is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -14.38, we must say that MRNS is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -14.38, MRNS is doing worse than 80.73% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-14.38

ROIC/WACCN/A

WACC10.82%

2.3 Liquidity

A Current Ratio of 2.28 indicates that MRNS has no problem at all paying its short term obligations.

MRNS has a Current ratio of 2.28. This is comparable to the rest of the industry: MRNS outperforms 41.15% of its industry peers.

MRNS has a Quick Ratio of 2.15. This indicates that MRNS is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of MRNS (2.15) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.28
Quick Ratio	2.15

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MRNS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.74%, which is quite good.

The Revenue has grown by 16.58% in the past year. This is quite good.

MRNS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 162.16% yearly.

EPS 1Y (TTM)11.74%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%1.64%

Revenue 1Y (TTM)16.58%

Revenue growth 3Y162.16%

Revenue growth 5YN/A

Sales Q2Q%32.48%

3.2 Future

MRNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.90% yearly.

MRNS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 55.05% yearly.

EPS Next Y24.71%

EPS Next 2Y31.45%

EPS Next 3Y22.37%

EPS Next 5Y17.9%

Revenue Next Year15.31%

Revenue Next 2Y23.55%

Revenue Next 3Y34.17%

Revenue Next 5Y55.05%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRNS. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRNS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MRNS's earnings are expected to grow with 22.37% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y31.45%

EPS Next 3Y22.37%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MRNS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MARINUS PHARMACEUTICALS INC

NASDAQ:MRNS (11/22/2024, 2:59:10 PM)

0.3178

0 (-1.4%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap17.50M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-171.37%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	90.62%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.35

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.28
Quick Ratio	2.15
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)11.74%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y24.71%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)16.58%

Revenue growth 3Y162.16%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

MARINUS PHARMACEUTICALS INC (MRNS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens